Literature DB >> 27256565

Depletion of CD4+ CD25+ regulatory T cells confers susceptibility to experimental autoimmune encephalomyelitis (EAE) in GM-CSF-deficient Csf2-/- mice.

Debjani Ghosh1, Alan D Curtis1, Daniel S Wilkinson1, Mark D Mannie2.   

Abstract

Previous studies established that GM-CSF-deficient (Csf2-deficient) mice exhibit profound resistance to experimental autoimmune encephalomyelitis. This study addressed whether the resistance of Csf2-deficient mice was a result of a requirement for GM-CSF in controlling the functional balance between effector and regulatory T cell subsets during experimental autoimmune encephalomyelitis. The main observation was that treatment with the anti-CD25 mAb PC61 rendered Csf2-deficient mice fully susceptible to severe, chronic experimental autoimmune encephalomyelitis, with disease incidences and severities equivalent to that of C57BL/6 mice. When both donors and recipients were treated with PC61 in a passive model of experimental autoimmune encephalomyelitis, adoptive transfer of myelin-specific Csf2-deficient T cells into Csf2-deficient recipients resulted in a nonresolving chronic course of severe paralytic experimental autoimmune encephalomyelitis. The peripheral Csf2-deficient T cell repertoire was marked by elevated CD3+ T cell frequencies that reflected substantial accumulations of naïve CD44null-low CD4+ and CD8+ T cells but essentially normal frequencies of CD4+ CD25+ forkhead box P3+ T cells among the CD3+ T cell pool. These findings suggested that Csf2-deficient mice had secondary deficiencies in peripheral T cell sensitization to environmental antigens. In accordance, myelin oligodendrocyte glycoprotein 35-55/CFA-sensitized Csf2-deficient mice exhibited deficient peripheral sensitization to myelin oligodendrocyte glycoprotein, whereas pretreatment of Csf2-deficient mice with PC61 enabled the robust induction of myelin oligodendrocyte glycoprotein-specific T cell responses in the draining lymphatics. In conclusion, the experimental autoimmune encephalomyelitis resistance of Csf2-deficient mice, at least in part, reflects a deficient induction of effector T cell function that cannot surmount normal regulatory T cell barriers. Experimental autoimmune encephalomyelitis effector responses, however, are unleashed upon depletion of regulatory CD25+ T cells. © Society for Leukocyte Biology.

Entities:  

Keywords:  FOXP3+ T cells; multiple sclerosis; neuroimmunology; tolerance

Mesh:

Substances:

Year:  2016        PMID: 27256565      PMCID: PMC5014742          DOI: 10.1189/jlb.3A0815-359R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  52 in total

Review 1.  The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis?

Authors:  Stefanie Kuerten; Paul V Lehmann
Journal:  J Interferon Cytokine Res       Date:  2011-09-21       Impact factor: 2.607

2.  Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis.

Authors:  Mandy L Ford; Brian D Evavold
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

3.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development.

Authors:  Naganari Ohkura; Masahide Hamaguchi; Hiromasa Morikawa; Kyoko Sugimura; Atsushi Tanaka; Yoshinaga Ito; Motonao Osaki; Yoshiaki Tanaka; Riu Yamashita; Naoko Nakano; Jochen Huehn; Hans Joerg Fehling; Tim Sparwasser; Kenta Nakai; Shimon Sakaguchi
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

Review 4.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

5.  Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice.

Authors:  I Mendel; A Katz; N Kozak; A Ben-Nun; M Revel
Journal:  Eur J Immunol       Date:  1998-05       Impact factor: 5.532

6.  Experimental autoimmune encephalomyelitis mediated by CD8+ T cells.

Authors:  Qingyong Ji; Joan Goverman
Journal:  Ann N Y Acad Sci       Date:  2007-03-21       Impact factor: 5.691

Review 7.  T(H)17 cytokines in autoimmune neuro-inflammation.

Authors:  Burkhard Becher; Benjamin M Segal
Journal:  Curr Opin Immunol       Date:  2011-09-09       Impact factor: 7.486

8.  Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function.

Authors:  Donald Cheatem; Balaji B Ganesh; Eryn Gangi; Chenthamarakshan Vasu; Bellur S Prabhakar
Journal:  Clin Immunol       Date:  2009-01-25       Impact factor: 3.969

Review 9.  Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

Authors:  Annika Deiß; Isabel Brecht; Axel Haarmann; Mathias Buttmann
Journal:  Expert Rev Neurother       Date:  2013-03       Impact factor: 4.618

10.  Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis.

Authors:  Noriko Komatsu; Kazuo Okamoto; Shinichiro Sawa; Tomoki Nakashima; Masatsugu Oh-hora; Tatsuhiko Kodama; Sakae Tanaka; Jeffrey A Bluestone; Hiroshi Takayanagi
Journal:  Nat Med       Date:  2013-12-22       Impact factor: 53.440

View more
  8 in total

Review 1.  Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells.

Authors:  Mark D Mannie; Kayla B DeOca; Alexander G Bastian; Cody D Moorman
Journal:  Cell Immunol       Date:  2020-07-15       Impact factor: 4.868

2.  IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.

Authors:  Duncheng Wang; Debjani Ghosh; S M Touhidul Islam; Cody D Moorman; Ashton E Thomason; Daniel S Wilkinson; Mark D Mannie
Journal:  J Immunol       Date:  2016-09-12       Impact factor: 5.422

3.  GM-CSF-Producing Th Cells in Rats Sensitive and Resistant to Experimental Autoimmune Encephalomyelitis.

Authors:  Zorica Stojić-Vukanić; Ivan Pilipović; Ivana Vujnović; Mirjana Nacka-Aleksić; Raisa Petrović; Nevena Arsenović-Ranin; Mirjana Dimitrijević; Gordana Leposavić
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

Review 4.  Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update.

Authors:  Noushin Lotfi; Rodolfo Thome; Nahid Rezaei; Guang-Xian Zhang; Abbas Rezaei; Abdolmohamad Rostami; Nafiseh Esmaeil
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

5.  A GM-CSF-neuroantigen tolerogenic vaccine elicits inefficient antigen recognition events below the CD40L triggering threshold to expand CD4+ CD25+ FOXP3+ Tregs that inhibit experimental autoimmune encephalomyelitis (EAE).

Authors:  Cody D Moorman; Alexander G Bastian; Kayla B DeOca; Mark D Mannie
Journal:  J Neuroinflammation       Date:  2020-06-10       Impact factor: 8.322

6.  Low-Zone IL-2 Signaling: Fusion Proteins Containing Linked CD25 and IL-2 Domains Sustain Tolerogenic Vaccination in vivo and Promote Dominance of FOXP3+ Tregs in vitro.

Authors:  Kayla B DeOca; Cody D Moorman; Brandon L Garcia; Mark D Mannie
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

7.  CCR6 and CXCR6 Identify the Th17 Cells With Cytotoxicity in Experimental Autoimmune Encephalomyelitis.

Authors:  Lifei Hou; Koichi Yuki
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

8.  A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4+ CD25high FOXP3+ Regulatory T Cells in Myelin-Specific TCR Transgenic Mice Contingent Upon Low-Efficiency T Cell Antigen Receptor Recognition.

Authors:  Cody D Moorman; Alan D Curtis; Alexander G Bastian; Sarah E Elliott; Mark D Mannie
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.